Ascendis reports Q3 2026 results as CNP therapy clears EU review, trial milestones advance
Ascendis posted Q3 2026 product revenue of 366 million euros and said EU regulators backed its CNP therapy for achondroplasia, with a final decision expected in the fourth quarter.
Ascendis Pharma said on November 12, 2026 that the European Medicines Agency's human medicines committee and its orphan drug committee issued favorable opinions supporting approval of once-weekly TransCon CNP to treat achondroplasia in children and backed keeping its orphan drug status in the EU1. The company said a final decision from the European Commission is expected during the fourth quarter of 2026, with the first European launch planned for Germany in the first quarter of 20271.
On the clinical side, Ascendis said it presented Week 52 data from the infant sentinel cohort of the reACHin Trial at ESPE 2026, showing that treatment with the once-weekly CNP therapy stabilized or improved foramen magnum stenosis in infants with achondroplasia under age 2, along with gains in linear growth1. Pivotal data from that program are expected in the third quarter of 2027.1 Separately, the company said it plans to begin enrolling patients in a Phase 3 trial of CNP monotherapy in children with hypochondroplasia and start a Phase 2 trial in adults with achondroplasia, both in the fourth quarter of 20261. For its growth hormone therapy SKYTROFA, Ascendis said its Phase 3 HighLiGHts basket trial spanning idiopathic short stature, SHOX deficiency, Turner syndrome and small for gestational age is expected to complete enrollment in the first half of 20271.
On financial results, Ascendis reported total product revenue for the third quarter of 2026 of 366 million euros, up 89% year over year1, and cash and cash equivalents of 964 million euros as of September 30, 2026, compared with 616 million euros at the end of 20251. The company said it expects full-year 2026 operating cash flow of at least 600 million euros1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.